Suppr超能文献

肠致病性大肠杆菌(ETEC)和志贺氏菌感染中抗原特异性 T 和 B 细胞在全身和黏膜免疫反应中的作用,及其作为疫苗开发中保护相关性的潜力。

Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development.

机构信息

PATH, Washington, DC, United States.

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.

出版信息

Vaccine. 2019 Aug 7;37(34):4787-4793. doi: 10.1016/j.vaccine.2019.03.040. Epub 2019 Jun 20.

Abstract

The generation of robust systemic and mucosal antibody and cell-mediated immune (CMI) responses that are protective, long-lasting, and can quickly be recalled upon subsequent re-exposure to the cognate antigen is the key to the development of effective vaccine candidates. These responses, whether they represent mechanistic or non-mechanistic immunological correlates of protection, usually entail the activation of T cell memory and effector subsets (T-CMI) and induction of long-lasting memory B cells. However, for ETEC and Shigella, the precise role of these key immune cells in primary and secondary (anamnestic) immune responses remains ill-defined. A workshop to address immune correlates for ETEC and Shigella, in general, and to elucidate the mechanistic role of T-cell subsets and B-cells, both systemically and in the mucosal microenvironment, in the development of durable protective immunity against ETEC and Shigella was held at the recent 2nd Vaccines against Shigella and ETEC (VASE) conference in June 2018. This report is a summary of the presentations and the discussion that ensued at the workshop.

摘要

产生强大的全身性和黏膜抗体以及细胞介导的免疫(CMI)反应,这些反应具有保护作用、持久且能够在随后再次接触同源抗原时迅速被召回,是开发有效疫苗候选物的关键。这些反应,无论是作为保护的机制或非机制免疫学相关性,通常需要激活 T 细胞记忆和效应亚群(T-CMI),并诱导持久的记忆 B 细胞。然而,对于 ETEC 和志贺氏菌,这些关键免疫细胞在原发性和继发性(回忆性)免疫反应中的确切作用仍未明确。为了确定 ETEC 和志贺氏菌的免疫相关性,并阐明 T 细胞亚群和 B 细胞在系统性和黏膜微环境中产生针对 ETEC 和志贺氏菌的持久保护性免疫中的机制作用,于 2018 年 6 月在最近举行的第 2 届志贺氏菌和肠产毒性大肠杆菌(ETEC)疫苗会议(VASE)上举办了一次研讨会。本报告是研讨会的报告摘要,包括演讲和讨论。

相似文献

6
Preface.前言。
Vaccine. 2019 Aug 7;37(34):4767. doi: 10.1016/j.vaccine.2019.06.085. Epub 2019 Jul 9.
8
Using advocacy to increase investment in enteric vaccine development.利用宣传倡导增加投入,促进肠道疫苗研发。
Vaccine. 2019 Aug 7;37(34):4811-4813. doi: 10.1016/j.vaccine.2018.12.033. Epub 2019 Feb 5.
10
Clinical endpoints for efficacy studies.疗效研究的临床终点。
Vaccine. 2019 Aug 7;37(34):4814-4822. doi: 10.1016/j.vaccine.2019.03.051. Epub 2019 Apr 10.

引用本文的文献

本文引用的文献

7
Correlates of protection for enteric vaccines.肠道疫苗的保护相关因素。
Vaccine. 2017 Jun 8;35(26):3355-3363. doi: 10.1016/j.vaccine.2017.05.005. Epub 2017 May 11.
9
Animal Enterotoxigenic Escherichia coli.动物产肠毒素大肠杆菌
EcoSal Plus. 2016 Oct;7(1). doi: 10.1128/ecosalplus.ESP-0006-2016.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验